Indication: For the treatment of malignant neoplasm of colon, rectum, and ovary
Pharmacology: Oxaliplatin selectively inhibits the synthesis of deoxyribonucleic acid (DNA). The guanine and cytosine content correlates with the degree of Oxaliplatin-induced cross-linking. At high concentrations of the drug, cellular RNA and protein synthesis are also suppressed.
Mechanism Of Action: after activationm it binds preferentially to the guanine and cytosine moieties of DNA, leading to cross-linking of DNA, thus inhibiting DNA synthesis and function.
Interactions:
DrugBank: Interactions for Oxaliplatin
Interactions for Oxaliplatin:
No specific cytochrome P450-based drug interaction studies have been conducted. No pharmacokinetic interaction
between 85 mg/m2 ELOXATIN and infusional 5-FU has been observed in patients treated every 2 weeks.
Increases of 5-FU plasma concentrations by approximately 20% have been observed with doses of 130 mg/m2
ELOXATIN dosed every 3 weeks. Since platinum containing species are eliminated primarily through the kidney,
clearance of these products may be decreased by coadministration of potentially nephrotoxic compounds; although, this
has not been specifically studied.
Chemical IUPAC Name: ethanedioate;platinum(+4)cation;(2-azanidylcyclohexyl)azanide
Chemical Formula: C8H12N2O4Pt
Half Life: Not Available
Drug Type: Approved Drug
# Accession No: APRD00186
CAS Registry Number: 61825-94-3
Oxaliplatin News (When available)
Hospital cancer drug funding approvedDec 18, 2005 Scoop.co.nz (press release), ...metastatic colorectal cancer. The change will see oxaliplatin (Eloxatin) made available as a first-line treatment. PHARMAC Medical ...
NCCN Updates Colon Cancer GuidelinesDec 22, 2005 Business Wire (press release), The panel also added a new regimen, capecitabine (Xeloda) and oxaliplatin (Eloxatin) also known as CAPOX as a treatment option in first-line therapy. ...
Home
Copyright phasechange.org 2006.
All Rights Reserved.
